Loading…
Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease
Background Sickle cell disease (SCD) has become a major public health issue. Hydroxyurea and red blood cell (RBC) transfusion are the cornerstone treatments. Erythrocytapheresis (ECP) is an automated method for transfusion exchange. Given that ECP requires more blood than conventional transfusion, t...
Saved in:
| Published in: | Transfusion (Philadelphia, Pa.) Pa.), 2015-02, Vol.55 (2), p.357-363 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4285-e921e1eed73c160d7e233db3817deb408d8764fa28e42e0dd3522f88f07ac6373 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4285-e921e1eed73c160d7e233db3817deb408d8764fa28e42e0dd3522f88f07ac6373 |
| container_end_page | 363 |
| container_issue | 2 |
| container_start_page | 357 |
| container_title | Transfusion (Philadelphia, Pa.) |
| container_volume | 55 |
| creator | Michot, Jean-Marie Driss, Françoise Guitton, Corinne Moh Klaren, Julia Lefebvre, François Chamillard, Xavier Gallon, Philippe Fourn, Erwan Pela, Alain M. Tertian, Gérard Le Bras, Philippe Chantalat-Auger, Christelle Delfraissy, Jean-François Goujard, Cécile Lambotte, Olivier |
| description | Background
Sickle cell disease (SCD) has become a major public health issue. Hydroxyurea and red blood cell (RBC) transfusion are the cornerstone treatments. Erythrocytapheresis (ECP) is an automated method for transfusion exchange. Given that ECP requires more blood than conventional transfusion, there is concern about alloimmunization and hemolytic transfusion reactions. We evaluate the incidence of hemolytic transfusion reactions and alloimmunization rates in patients receiving conventional blood transfusions and in patients participating in long‐term blood exchange programs with ECP.
Study Design and Methods
All hemolytic transfusion reactions and alloimmunizations in SCD patients were recorded over the period 2006 to 2011. Conventional transfusions and ECP were compared.
Results
The cohort consisted of 188 SCD patients. The median (±SD) age was 23 (±14) years. The ECP and conventional transfusion groups comprised 49 and 139 patients, respectively. The prevalence of alloimmunization was 33% in the ECP group and 22% in the conventional transfusion group (p = 0.1797). The alloimmunization/RBC unit (RBCU) ratio was lower in the ECP group than in the conventional transfusion group (1.6 and 11.6 per 1000, respectively; p |
| doi_str_mv | 10.1111/trf.12875 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_inserm_01995062v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3589367861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4285-e921e1eed73c160d7e233db3817deb408d8764fa28e42e0dd3522f88f07ac6373</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EosuWA38AWeICEmn9kdjJsdp-wtJKqKgSF8vrTBq3ib3YCe3-e7yk3QMScxlp9Myrd-ZF6B0lBzTV4RCaA8pKWbxAM1pwmbGqKl6iGSE5zSjlbA-9ifGOEMIqQl-jPVawgspczFB30fej8y30evCdv7UGpw5BOwPYN9i0wbvtME1iM0brHYZH02p3CxE_2KHFEDZDosxm0OsWAkQbsXU4WnPfATbQdbi2EXSEffSq0V2Et099jn6cnlwvzrPl1dnF4miZmZyVRQYVo0ABaskNFaSWwDivV7yksoZVTsq6lCJvNCshZ0DqmheMNWXZEKmN4JLP0edJt9WdWgfb67BRXlt1frRU1kUIvSI0_YgI9psm_OOEr4P_NUIcVG_j1rd24MeoqCgKybgQVUI__IPe-TG4dMyWyisuquR1jj5NlAk-xgDNzgQlapuYSompv4kl9v2T4rjqod6RzxEl4HACHmwHm_8rqevvp8-S2bRh4wCPuw0d7pWQPJE3l2fq29fqcvHzy7G64X8AS2qwKg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1654936923</pqid></control><display><type>article</type><title>Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Michot, Jean-Marie ; Driss, Françoise ; Guitton, Corinne ; Moh Klaren, Julia ; Lefebvre, François ; Chamillard, Xavier ; Gallon, Philippe ; Fourn, Erwan ; Pela, Alain M. ; Tertian, Gérard ; Le Bras, Philippe ; Chantalat-Auger, Christelle ; Delfraissy, Jean-François ; Goujard, Cécile ; Lambotte, Olivier</creator><creatorcontrib>Michot, Jean-Marie ; Driss, Françoise ; Guitton, Corinne ; Moh Klaren, Julia ; Lefebvre, François ; Chamillard, Xavier ; Gallon, Philippe ; Fourn, Erwan ; Pela, Alain M. ; Tertian, Gérard ; Le Bras, Philippe ; Chantalat-Auger, Christelle ; Delfraissy, Jean-François ; Goujard, Cécile ; Lambotte, Olivier</creatorcontrib><description>Background
Sickle cell disease (SCD) has become a major public health issue. Hydroxyurea and red blood cell (RBC) transfusion are the cornerstone treatments. Erythrocytapheresis (ECP) is an automated method for transfusion exchange. Given that ECP requires more blood than conventional transfusion, there is concern about alloimmunization and hemolytic transfusion reactions. We evaluate the incidence of hemolytic transfusion reactions and alloimmunization rates in patients receiving conventional blood transfusions and in patients participating in long‐term blood exchange programs with ECP.
Study Design and Methods
All hemolytic transfusion reactions and alloimmunizations in SCD patients were recorded over the period 2006 to 2011. Conventional transfusions and ECP were compared.
Results
The cohort consisted of 188 SCD patients. The median (±SD) age was 23 (±14) years. The ECP and conventional transfusion groups comprised 49 and 139 patients, respectively. The prevalence of alloimmunization was 33% in the ECP group and 22% in the conventional transfusion group (p = 0.1797). The alloimmunization/RBC unit (RBCU) ratio was lower in the ECP group than in the conventional transfusion group (1.6 and 11.6 per 1000, respectively; p < 0.0001). Although patients in the ECP group received more than 10 times more RBCUs than patients in the conventional transfusion group (206 vs. 19 RBCUs per patient, respectively; p < 0.0001), none of the four recorded hemolytic transfusion reactions (n = 4) occurred.
Conclusion
Regarding alloimmunization, ECP exhibits a good immunohematologic safety profile relative to conventional transfusion in a large SCD mainly adult cohort.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.12875</identifier><identifier>PMID: 25251746</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Anemia, Sickle Cell - therapy ; Child ; Cytapheresis ; Erythrocyte Transfusion ; Female ; Hemolysis ; Humans ; Immune Tolerance ; Immunology ; Incidence ; Life Sciences ; Male ; Santé publique et épidémiologie</subject><ispartof>Transfusion (Philadelphia, Pa.), 2015-02, Vol.55 (2), p.357-363</ispartof><rights>2014 AABB</rights><rights>2014 AABB.</rights><rights>2015 AABB</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4285-e921e1eed73c160d7e233db3817deb408d8764fa28e42e0dd3522f88f07ac6373</citedby><cites>FETCH-LOGICAL-c4285-e921e1eed73c160d7e233db3817deb408d8764fa28e42e0dd3522f88f07ac6373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25251746$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-01995062$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Michot, Jean-Marie</creatorcontrib><creatorcontrib>Driss, Françoise</creatorcontrib><creatorcontrib>Guitton, Corinne</creatorcontrib><creatorcontrib>Moh Klaren, Julia</creatorcontrib><creatorcontrib>Lefebvre, François</creatorcontrib><creatorcontrib>Chamillard, Xavier</creatorcontrib><creatorcontrib>Gallon, Philippe</creatorcontrib><creatorcontrib>Fourn, Erwan</creatorcontrib><creatorcontrib>Pela, Alain M.</creatorcontrib><creatorcontrib>Tertian, Gérard</creatorcontrib><creatorcontrib>Le Bras, Philippe</creatorcontrib><creatorcontrib>Chantalat-Auger, Christelle</creatorcontrib><creatorcontrib>Delfraissy, Jean-François</creatorcontrib><creatorcontrib>Goujard, Cécile</creatorcontrib><creatorcontrib>Lambotte, Olivier</creatorcontrib><title>Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>Background
Sickle cell disease (SCD) has become a major public health issue. Hydroxyurea and red blood cell (RBC) transfusion are the cornerstone treatments. Erythrocytapheresis (ECP) is an automated method for transfusion exchange. Given that ECP requires more blood than conventional transfusion, there is concern about alloimmunization and hemolytic transfusion reactions. We evaluate the incidence of hemolytic transfusion reactions and alloimmunization rates in patients receiving conventional blood transfusions and in patients participating in long‐term blood exchange programs with ECP.
Study Design and Methods
All hemolytic transfusion reactions and alloimmunizations in SCD patients were recorded over the period 2006 to 2011. Conventional transfusions and ECP were compared.
Results
The cohort consisted of 188 SCD patients. The median (±SD) age was 23 (±14) years. The ECP and conventional transfusion groups comprised 49 and 139 patients, respectively. The prevalence of alloimmunization was 33% in the ECP group and 22% in the conventional transfusion group (p = 0.1797). The alloimmunization/RBC unit (RBCU) ratio was lower in the ECP group than in the conventional transfusion group (1.6 and 11.6 per 1000, respectively; p < 0.0001). Although patients in the ECP group received more than 10 times more RBCUs than patients in the conventional transfusion group (206 vs. 19 RBCUs per patient, respectively; p < 0.0001), none of the four recorded hemolytic transfusion reactions (n = 4) occurred.
Conclusion
Regarding alloimmunization, ECP exhibits a good immunohematologic safety profile relative to conventional transfusion in a large SCD mainly adult cohort.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anemia, Sickle Cell - therapy</subject><subject>Child</subject><subject>Cytapheresis</subject><subject>Erythrocyte Transfusion</subject><subject>Female</subject><subject>Hemolysis</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>Immunology</subject><subject>Incidence</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Santé publique et épidémiologie</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kU1v1DAQhi0EosuWA38AWeICEmn9kdjJsdp-wtJKqKgSF8vrTBq3ib3YCe3-e7yk3QMScxlp9Myrd-ZF6B0lBzTV4RCaA8pKWbxAM1pwmbGqKl6iGSE5zSjlbA-9ifGOEMIqQl-jPVawgspczFB30fej8y30evCdv7UGpw5BOwPYN9i0wbvtME1iM0brHYZH02p3CxE_2KHFEDZDosxm0OsWAkQbsXU4WnPfATbQdbi2EXSEffSq0V2Et099jn6cnlwvzrPl1dnF4miZmZyVRQYVo0ABaskNFaSWwDivV7yksoZVTsq6lCJvNCshZ0DqmheMNWXZEKmN4JLP0edJt9WdWgfb67BRXlt1frRU1kUIvSI0_YgI9psm_OOEr4P_NUIcVG_j1rd24MeoqCgKybgQVUI__IPe-TG4dMyWyisuquR1jj5NlAk-xgDNzgQlapuYSompv4kl9v2T4rjqod6RzxEl4HACHmwHm_8rqevvp8-S2bRh4wCPuw0d7pWQPJE3l2fq29fqcvHzy7G64X8AS2qwKg</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Michot, Jean-Marie</creator><creator>Driss, Françoise</creator><creator>Guitton, Corinne</creator><creator>Moh Klaren, Julia</creator><creator>Lefebvre, François</creator><creator>Chamillard, Xavier</creator><creator>Gallon, Philippe</creator><creator>Fourn, Erwan</creator><creator>Pela, Alain M.</creator><creator>Tertian, Gérard</creator><creator>Le Bras, Philippe</creator><creator>Chantalat-Auger, Christelle</creator><creator>Delfraissy, Jean-François</creator><creator>Goujard, Cécile</creator><creator>Lambotte, Olivier</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>201502</creationdate><title>Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease</title><author>Michot, Jean-Marie ; Driss, Françoise ; Guitton, Corinne ; Moh Klaren, Julia ; Lefebvre, François ; Chamillard, Xavier ; Gallon, Philippe ; Fourn, Erwan ; Pela, Alain M. ; Tertian, Gérard ; Le Bras, Philippe ; Chantalat-Auger, Christelle ; Delfraissy, Jean-François ; Goujard, Cécile ; Lambotte, Olivier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4285-e921e1eed73c160d7e233db3817deb408d8764fa28e42e0dd3522f88f07ac6373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anemia, Sickle Cell - therapy</topic><topic>Child</topic><topic>Cytapheresis</topic><topic>Erythrocyte Transfusion</topic><topic>Female</topic><topic>Hemolysis</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>Immunology</topic><topic>Incidence</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Santé publique et épidémiologie</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michot, Jean-Marie</creatorcontrib><creatorcontrib>Driss, Françoise</creatorcontrib><creatorcontrib>Guitton, Corinne</creatorcontrib><creatorcontrib>Moh Klaren, Julia</creatorcontrib><creatorcontrib>Lefebvre, François</creatorcontrib><creatorcontrib>Chamillard, Xavier</creatorcontrib><creatorcontrib>Gallon, Philippe</creatorcontrib><creatorcontrib>Fourn, Erwan</creatorcontrib><creatorcontrib>Pela, Alain M.</creatorcontrib><creatorcontrib>Tertian, Gérard</creatorcontrib><creatorcontrib>Le Bras, Philippe</creatorcontrib><creatorcontrib>Chantalat-Auger, Christelle</creatorcontrib><creatorcontrib>Delfraissy, Jean-François</creatorcontrib><creatorcontrib>Goujard, Cécile</creatorcontrib><creatorcontrib>Lambotte, Olivier</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michot, Jean-Marie</au><au>Driss, Françoise</au><au>Guitton, Corinne</au><au>Moh Klaren, Julia</au><au>Lefebvre, François</au><au>Chamillard, Xavier</au><au>Gallon, Philippe</au><au>Fourn, Erwan</au><au>Pela, Alain M.</au><au>Tertian, Gérard</au><au>Le Bras, Philippe</au><au>Chantalat-Auger, Christelle</au><au>Delfraissy, Jean-François</au><au>Goujard, Cécile</au><au>Lambotte, Olivier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2015-02</date><risdate>2015</risdate><volume>55</volume><issue>2</issue><spage>357</spage><epage>363</epage><pages>357-363</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>Background
Sickle cell disease (SCD) has become a major public health issue. Hydroxyurea and red blood cell (RBC) transfusion are the cornerstone treatments. Erythrocytapheresis (ECP) is an automated method for transfusion exchange. Given that ECP requires more blood than conventional transfusion, there is concern about alloimmunization and hemolytic transfusion reactions. We evaluate the incidence of hemolytic transfusion reactions and alloimmunization rates in patients receiving conventional blood transfusions and in patients participating in long‐term blood exchange programs with ECP.
Study Design and Methods
All hemolytic transfusion reactions and alloimmunizations in SCD patients were recorded over the period 2006 to 2011. Conventional transfusions and ECP were compared.
Results
The cohort consisted of 188 SCD patients. The median (±SD) age was 23 (±14) years. The ECP and conventional transfusion groups comprised 49 and 139 patients, respectively. The prevalence of alloimmunization was 33% in the ECP group and 22% in the conventional transfusion group (p = 0.1797). The alloimmunization/RBC unit (RBCU) ratio was lower in the ECP group than in the conventional transfusion group (1.6 and 11.6 per 1000, respectively; p < 0.0001). Although patients in the ECP group received more than 10 times more RBCUs than patients in the conventional transfusion group (206 vs. 19 RBCUs per patient, respectively; p < 0.0001), none of the four recorded hemolytic transfusion reactions (n = 4) occurred.
Conclusion
Regarding alloimmunization, ECP exhibits a good immunohematologic safety profile relative to conventional transfusion in a large SCD mainly adult cohort.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25251746</pmid><doi>10.1111/trf.12875</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1132 |
| ispartof | Transfusion (Philadelphia, Pa.), 2015-02, Vol.55 (2), p.357-363 |
| issn | 0041-1132 1537-2995 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_inserm_01995062v1 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adolescent Adult Anemia, Sickle Cell - therapy Child Cytapheresis Erythrocyte Transfusion Female Hemolysis Humans Immune Tolerance Immunology Incidence Life Sciences Male Santé publique et épidémiologie |
| title | Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A27%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohematologic%20tolerance%20of%20chronic%20transfusion%20exchanges%20with%20erythrocytapheresis%20in%20sickle%20cell%20disease&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Michot,%20Jean-Marie&rft.date=2015-02&rft.volume=55&rft.issue=2&rft.spage=357&rft.epage=363&rft.pages=357-363&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/trf.12875&rft_dat=%3Cproquest_hal_p%3E3589367861%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4285-e921e1eed73c160d7e233db3817deb408d8764fa28e42e0dd3522f88f07ac6373%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1654936923&rft_id=info:pmid/25251746&rfr_iscdi=true |